FDA Grants Approval for Glycopyrrolate ANDA216910 by Quagen
The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Glycopyrrolate submitted by Quagen.
Asset
Quagen
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Quagen's generic Glycopyrrolate presents a significant shift in the competitive landscape for respiratory therapies. Pharma companies must evaluate the potential impact on pricing and market share of their existing Glycopyrrolate products to maintain competitive positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry date and pricing strategies of Quagen's Glycopyrrolate product.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.